-+ 0.00%
-+ 0.00%
-+ 0.00%
MSD: The TROFUSE-015 trial evaluating SACITUZUMAB TIRUMOTECAN reached the main end point, improving overall survival by one-third.
Share
Listen to the news
MSD: The TROFUSE-015 trial evaluating SACITUZUMAB TIRUMOTECAN reached the main end point, improving overall survival by one-third.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending